Herantis Pharma Plc

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinsons disease. Herantis lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. A Phase 1a clinical trial has demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland

'parkinson''s disease,neurodegenerative diseases,biologics,biotech,and drug development'

Herantis pharma plc operates in the Biotechnology research industry.

Herantis pharma plc's HQ phone number is 18082811424

Herantis pharma plc's revenue is 11m - 100m

Herantis pharma plc has 11 - 50 employees.